UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 322

Sortiert nach

Mitochondrial transcription factor A regulates mitochondrial transcription initiation, DNA packaging, and genome copy number

Biochimica et biophysica acta, 2012-09, Vol.1819 (9-10), p.921-929

2012

Volltextzugriff (PDF)

Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma

International journal of molecular sciences, 2023-02, Vol.24 (3), p.2858

2023

Volltextzugriff (PDF)

Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer

American journal of health-system pharmacy, 2020-03, Vol.77 (5), p.346-351

2020

Volltextzugriff (PDF)

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

Journal of clinical oncology, 2013-04, Vol.31 (11), p.1405-1414

2013

Volltextzugriff (PDF)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

PloS one, 2021-08, Vol.16 (8), p.e0254205-e0254205

2021

Volltextzugriff (PDF)

Prevention and treatment of chemotherapy-induced peripheral neuropathy

American journal of health-system pharmacy, 2014-01, Vol.71 (1), p.19-25

2014

Volltextzugriff (PDF)

Estimating the distribution of ratio of paired event times in phase II oncology trials

Statistics in medicine, 2023-02, Vol.42 (3), p.388-406

2023

Volltextzugriff (PDF)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky

PloS one, 2020-08, Vol.15 (8), p.e0237790-e0237790

2020

Volltextzugriff (PDF)

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

PloS one, 2017-06, Vol.12 (6), p.e0178593-e0178593

2017

Volltextzugriff (PDF)

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma

American journal of health-system pharmacy, 2016-02, Vol.73 (4), p.193-201

2016

Volltextzugriff (PDF)

DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden

PloS one, 2020-12, Vol.15 (12), p.e0244558-e0244558

2020

Volltextzugriff (PDF)

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer

Diagnostics (Basel), 2020-05, Vol.10 (5), p.279

2020

Volltextzugriff (PDF)

Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells

Scientific reports, 2023-12, Vol.13 (1), p.22383-22383, Article 22383

2023

Volltextzugriff (PDF)

Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al

Journal of clinical oncology, 2018-10, Vol.36 (30), p.3065-3066

2018

Volltextzugriff (PDF)

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer

International journal of molecular sciences, 2023-09, Vol.24 (18), p.14212

2023

Volltextzugriff (PDF)

Mutation in TACO1 , encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome

Nature genetics, 2009-07, Vol.41 (7), p.833-837

2009

Volltextzugriff (PDF)

MCUR1 is an essential component of mitochondrial Ca2+ uptake that regulates cellular metabolism

Nature cell biology, 2012-12, Vol.14 (12), p.1336

2012

Volltextzugriff (PDF)

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy

Cancers, 2022-04, Vol.14 (9), p.2220

2022

Volltextzugriff (PDF)

Low-Fat Abiraterone Food Effect Is of Little Consequence

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1385-1386

2018

Volltextzugriff (PDF)

Editorial: Anticancer Potential of Artemisia annua

Frontiers in oncology, 2022-02, Vol.12, p.853406-853406

2022

Volltextzugriff (PDF)

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

Journal of clinical oncology, 2010-07, Vol.28 (21), p.3491-3497

2010

Volltextzugriff (PDF)

Precision medicine: Opportunities for health-system pharmacists

American journal of health-system pharmacy, 2021-05, Vol.78 (11), p.999-1003

2021

Volltextzugriff (PDF)

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer

American journal of health-system pharmacy, 2015-09, Vol.72 (17), p.1456-1462

2015

Volltextzugriff (PDF)

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

JCO precision oncology, 2021-07, Vol.5

2021

Volltextzugriff (PDF)

Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design

European journal of cancer prevention, 2024-01, Vol.33 (1), p.69

2024

Volltextzugriff (PDF)

1 – 25 von 322

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(307)
Mit Volltextzugriff
(303)

Publikationsform

Sprache

Englisch
(322)
Japanisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(191)
Life Sciences & Biomedicine
(182)
Humans
(147)
Oncology
(97)
Pharmacology & Pharmacy
(82)
Female
(72)
Male
(67)
Middle Aged
(57)
Aged
(48)
Biological And Medical Sciences
(43)
Tumors
(43)
Medical Sciences
(42)
Chemotherapy
(37)
Mutation
(35)
Antineoplastic Agents
(33)
Antineoplastic Agents - Therapeutic Use
(32)
Adult
(31)
Cancer Therapies
(30)
Neoplasms - Drug Therapy
(29)
Pharmacology. Drug Treatments
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mitochondrial transcription factor A regulates mitochondrial transcription initiation, DNA packaging, and genome copy number

Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma

Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

Prevention and treatment of chemotherapy-induced peripheral neuropathy

Estimating the distribution of ratio of paired event times in phase II oncology trials

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma

DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer

Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells

Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer

Mutation in TACO1 , encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome

MCUR1 is an essential component of mitochondrial Ca2+ uptake that regulates cellular metabolism

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy

Low-Fat Abiraterone Food Effect Is of Little Consequence

Editorial: Anticancer Potential of Artemisia annua

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

Precision medicine: Opportunities for health-system pharmacists

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design

Suchergebnisse filtern